SCHEMBL13330656

SCHEMBL13330656

Cc1ccc2c(c1)c1cc(C)ccc1c1nccnc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 5/20 0.50
CCR8 P51685 5/20 0.50
CCR5 P51681 4/20 0.50
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 1/20 0.43
HSP90AA1 P07900 1/20 0.43
ACHE P22303 1/20 0.41
UHRF1 Q96T88 1/20 0.41
KDM4E B2RXH2 2/20 0.40
HTR1A P08908 2/20 0.39
ADRA1D P25100 2/20 0.39
ADRA1A P35348 2/20 0.39
ADRA1B P35368 2/20 0.39
MEN1 O00255 1/20 0.38
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPK1 P28482 1/20 0.38
MAP2K4 P45985 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10001030 0.92 NPC1 (0.47) CCR1CCR8CCR5L3MBTL1NPC1
SCHEMBL13330657 0.91 CCR1 (0.50) CCR1CCR8CCR5L3MBTL1NPC1
SCHEMBL13492546 0.88 CCR1 (0.41) CCR1CCR8CCR5L3MBTL1NPC1
SCHEMBL12346093 0.87 L3MBTL1 (0.57) CCR1CCR8CCR5L3MBTL1NPC1
SCHEMBL20193202 0.87 NPC1 (0.47) CCR1CCR8CCR5L3MBTL1NPC1
SCHEMBL10084894 0.83 CCR1 (0.43) CCR1CCR8CCR5L3MBTL1NPC1
SCHEMBL10001027 0.81 NPC1 (0.50) CCR1CCR8CCR5L3MBTL1NPC1
SCHEMBL10001029 0.81 NPC1 (0.50) CCR1CCR8CCR5L3MBTL1NPC1
SCHEMBL17994960 0.81 NPC1 (0.50) CCR1CCR8CCR5L3MBTL1NPC1
SCHEMBL19978073 0.77 NPC1 (0.50) CCR1CCR8CCR5L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11508927-B2 Organic electroluminescence device, preparation method thereof and display apparatus KUNSHAN GO-VISIONOX OPTO-ELECTRONICS CO., LTD (CN) 2022-11-22 US disclosed
US-20200203652-A1 ORGANIC ELECTROLUMINESCENCE DEVICE, PREPARATION METHOD THEREOF AND DISPLAY APPARATUS KUNSHAN GO-VISIONOX OPTO-ELECTRONICS CO., LTD (CN) 2020-06-25 US disclosed
US-9353065-B2 Heterocyclic bridged biphenyls BASF SE (DE) 2016-05-31 US disclosed
US-20100109514-A1 HETEROCYCLIC BRIDGED BIPHENYLS UDC IRELAND LIMITED (IE) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100109514-A1 HETEROCYCLIC BRIDGED BIPHENYLS OCIAD1, SBDS, OCIAD2 CCR1 4387/4885CCR8 4781/4885CCR5 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.